Associated Genetic Biomarkers
NCI Definition: A morphologic finding indicating tissue infiltration by non-neoplastic or neoplastic histiocytes. 
Histiocytosiss most frequently harbor alterations in MAP2K1, TNFRSF14, SETD2, RPS6KB2, and PRDM1 .
MAP2K1 Mutation, TNFRSF14 X184_splice, SETD2 R1625H, SETD2 Mutation, and RPS6KB2 V422I are the most common alterations in histiocytosis .
There are 2 clinical trials for histiocytosis, of which 2 are open and 0 are completed or closed. Of the trials that contain histiocytosis as an inclusion criterion, 1 is phase 1/phase 2 (1 open) and 1 is phase 2 (1 open).
BRAF is the most frequent gene inclusion criterion for histiocytosis clinical trials .
Braf inhibitor plx8394 and cobimetinib are the most common interventions in histiocytosis clinical trials.
Significant Genes in Histiocytosis
BRAF is an inclusion eligibility criterion in 2 clinical trials for histiocytosis, of which 2 are open and 0 are closed. Of the trials that contain BRAF status and histiocytosis as inclusion criteria, 1 is phase 1/phase 2 (1 open) and 1 is phase 2 (1 open) .
Braf inhibitor plx8394 and cobimetinib are the most frequent therapies in histiocytosis trials with BRAF mutations as inclusion criteria .
2. The AACR Project GENIE Consortium. AACR Project GENIE: powering precision medicine through an international consortium. Cancer Discovery. 2017;7(8):818-831. Dataset Version 4. This dataset does not represent the totality of the genetic landscape; see paper for more information.